Refractory Advanced Cutaneous Melanoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Refractory Advanced Cutaneous Melanoma (CM), an aggressive cancer with a high potential for spreading, develops from pigment-forming melanoma cells in the skin. Even though cutaneous melanoma makes up only 5% of all skin cancers, it is the cause of the majority of skin cancer-related deaths worldwide. The first medication to significantly raise patient survival rates was immune checkpoint inhibition. Melanoma is a cancerous tumor that primarily affects white people. However, mortality rates are higher among African-Americans and Hispanics, and they are also more likely to develop melanoma and advanced disease. For the treatment of localized melanoma following total surgical resection, a number of adjuvant therapies have been investigated. Adjuvant chemotherapy, nonspecific immunotherapy, radiation therapy, retinoid therapy, vitamin therapy, and biologic therapy didn't improve overall survival (OS).

Description

Refractory Advanced Cutaneous Melanoma (CM), an aggressive cancer with a high propensity for spreading, develops from pigment-forming melanoma cells in the skin. Even though cutaneous melanoma makes up only 5% of all skin cancers, it is the cause of the majority of skin cancer-related deaths worldwide. The first medication to significantly raise patient survival rates was immune checkpoint inhibition. The immunosuppressive tumor microenvironment and intrinsic and acquired melanoma therapy resistance, however, continue to be significant obstacles. Anywhere on the skin, including the palms of the hands, the soles of the feet, the spaces in between the toes and fingers, and the areas under the toenails, can develop this kind of melanoma. The most prevalent indicators of skin cancer are acne and new or changing moles. Near the edges of pigmented lesions, most melanoma patients notice an increase in color, diameter, height, or asymmetry. This is particularly true for people who have numerous moles, clinically abnormal moles, and a history of non-melanoma skin cancer (e.g., a history of skin cancer in the family). The traditional subtypes of histiocytic melanoma include lenticular, nodular, and superficial proliferation. The distinction between these subtypes is made according to the histologic growth pattern (mostly in particular translational types, superficial foliar spread, and percutaneous nodular types), anatomic location, and level of solar damage. A thorough history, planning review, and physical examination are the three most crucial steps in the initial workup of a patient with cutaneous melanoma. Sentinel lymph node biopsy (SLNB) is typically recommended for pathological staging of regional lymph nodes in primary tumors that are deeper than 1 mm and have certain unfavourable histologic characteristics (e.g., lymphatic invasion, an increased rate of mitosis, and ulceration). less thick melanomas.

Refractory Advanced Cutaneous Melanoma (Epidemiology)

Skin cancer cases are on the rise everywhere, with rates in Australia and New Zealand still being higher. The incidence of skin cancer has, however, decreased by -0.7% annually in Australia since 2005. This decline may be attributed to the 40 years of effective primary prevention campaigns. According to the most recent analysis of global melanoma statistics from 2020, Australia and New Zealand had age-standardized incidence rates of 36.6 cases per 100,000 men and women and 31.6 cases per 100,000 men and women, respectively, compared to the United States, which had 16.6 cases per 100,000 men and women. Mostly affecting white people, melanoma is a cancerous tumor. However, mortality rates are higher among African-Americans and Hispanics, and they are also more likely to develop melanoma and advanced disease. Invasive melanoma is more common in women in the US between the ages of 15 and 49 (1 in 156 versus 1 in 230 men in 2021). Melanoma, on the other hand, is prevalent in men over 50 and affects 1 in 27 men and 1 in 40 women over the course of their lifetime. Men will be slightly more impacted than women globally in 2020, with 173,844 and 150,791 new cases, respectively. However, men outnumbered women significantly (32,385 to 24,658, respectively) among the 57,043 fatalities recorded globally in 2020. Melanoma is typically diagnosed at 65 years of age. However, it is the second most prevalent cancer in women aged 30 to 34, right behind breast cancer, and the most prevalent cancer in women between the ages of 25 and 29. From 2010 to 2014, the incidence of melanoma declined slightly in young white men and non-Hispanic women but continued to increase significantly in men over 54 and women over 44. The age group of people over 65 years old showed the greatest differences in melanoma incidence and mortality. Age-related mortality and morbidity varied less between individuals older than 50 years and those younger than 50 years. Older adults are more likely to develop and die from skin cancer (especially white men aged 65 and older), making them a prime target for early detection and screening. Treatment options for older adults may also be limited by comorbidities, intolerance of side effects or toxicity, increased potential for drug interactions, and potential exclusion from clinical trials based on age criteria, but newer immunology and targeted therapies are available to many patients.

Refractory Advanced Cutaneous Melanoma -Current Market Size & Forecast Trends

The market for refractory advanced cutaneous melanoma is expected to grow significantly, with projections indicating it will reach approximately USD 14.71 billion by 2029, growing at a compound annual growth rate (CAGR) of 12.1%. This growth is driven by an increasing number of patients, advancements in immunotherapy and targeted treatments, and rising awareness of melanoma due to increased UV exposure. North America is expected to lead the market due to its strong healthcare infrastructure and ongoing research efforts. Overall, the refractory advanced cutaneous melanoma market is well-positioned for substantial growth through 2035 as new therapies continue to emerge and improve patient outcomes.

The treatment of localized melanoma following total surgical resection has been studied using a variety of adjuvant therapies. Adjuvant chemotherapy, non-specific immunotherapy, radiation, retinoid, vitamin, or biologic therapy did not improve overall survival (OS). The first FDA-approved adjuvant therapy for the treatment of high-risk cutaneous melanoma (currently defined as stage IIB, IIC, and III) was high-dose IFN alfa-2b, but newer immunologic techniques have since supplanted it. The field of adjuvant, novel, and systemic treatments for stage III and IV melanoma has undergone a significant transformation with the introduction of modern immunotherapy, immune checkpoint blockade, and targeted therapies targeting particular tumor mutations. A CTLA-4 immune checkpoint inhibitor known as ipilimumab (Yervoy) was approved in 2015 for the adjuvant treatment of stage III melanoma, including pathological involvement of regional lymph nodes larger than 1 mm. good lymph nodes. Adjuvant therapy was approved based on the findings of the EORTC 18071 study, which looked at 951 high-risk patients with stage III melanoma who underwent total lymph node dissection. At one year, ipilimumab significantly improved relapse-free survival (RFS) compared to a 1 year (63.5% vs. 56.1%), 2 years (51.5% vs. 43.8%), and 3 years (46.5% against 34.8%) was the same as the median RFS in the ipilimumab group (26.1 months vs. 17.1 months). The first adjuvant ipilimumab regimen approved by the FDA, however, had a dose and duration that were significantly higher than those permitted for melanoma patients (3 mg/kg per week for 4 doses, then every 3 months for up to 3 years).

Report Highlights

Refractory Advanced Cutaneous Melanoma - Current Market Trends

Refractory Advanced Cutaneous Melanoma - Current & Forecasted Cases across the G8 Countries

Refractory Advanced Cutaneous Melanoma - Market Opportunities and Sales Potential for Agents

Refractory Advanced Cutaneous Melanoma - Patient-based Market Forecast to 2035

Refractory Advanced Cutaneous Melanoma - Untapped Business Opportunities

Refractory Advanced Cutaneous Melanoma - Product Positioning Vis-a-vis Competitors' Products

Refractory Advanced Cutaneous Melanoma - KOLs Insight